Dual Actions of Ketorolac in Metastatic Ovarian Cancer.

Hudson, Laurie G; Cook, Linda S; Grimes, Martha M; Muller, Carolyn Y; Adams, Sarah F; Wandinger-Ness, Angela

Hudson, Laurie G; Cook, Linda S; Grimes, Martha M; Muller, Carolyn Y; Adams, Sarah F; Wandinger-Ness, Angela.

Afiliación

Hudson LG; Department of Pharmaceutical Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. lhudson@salud.unm.edu.
Cook LS; Department of Internal Medicine, Division of Epidemiology and Biostatistics, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Grimes MM; Department of Pharmaceutical Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Muller CY; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Adams SF; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Wandinger-Ness A; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Cancers (Basel) ; 11(8)2019 Jul 24.

Article en En | MEDLINE | ID: mdl-31344967

Palabras clave

Cdc42; Rac1; ketorolac; metastasis; non-steroidal anti-inflammatory drug (NSAID); ovarian cancer; peri-operative period; therapeutic targets

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos